M. Andersen, Development of physiologically based pharmacokinetic and physiologically based pharmacodymamic models for applications in toxicology and risk assessment, Toxicology Letters, vol.79, issue.1-3, pp.35-44, 1995.
DOI : 10.1016/0378-4274(95)03355-O

A. Bailer and D. Dankovic, An introduction to the use of physiologically based pharmacokinetic models in risk assessment, Statistical Methods in Medical Research, vol.91, issue.4, pp.341-58, 1997.
DOI : 10.1177/096228029700600404

M. Rowland and T. Tozer, Clinical Pharmacokinetics: Concepts and Applications, 1989.

L. Gerlowski and R. Jain, Physiologically Based Pharmacokinetic Modeling: Principles and Applications, Journal of Pharmaceutical Sciences, vol.72, issue.10, pp.1103-1130, 1983.
DOI : 10.1002/jps.2600721003

L. Balant and M. Gex-fabry, Review Physiological pharmacokinetic modelling, Xenobiotica, vol.18, issue.11, pp.1241-57, 1990.
DOI : 10.3109/03602538409033558

M. Mezzetti, J. Ibrahim, F. Bois, L. Ryan, L. Ngo et al., A Bayesian compartmental model for the evaluation of 1,3-butadiene metabolism, Journal of the Royal Statistical Society: Series C (Applied Statistics), vol.50, issue.3, pp.291-305, 2003.
DOI : 10.1016/S0009-2797(01)00180-6

URL : https://hal.archives-ouvertes.fr/ineris-00962856

M. Kohn and R. Melnick, Species differences in the production and clearance of 1,3-butadiene metabolites: a mechanistic model indicates predominantly physiological, not biochemical, control, Carcinogenesis, vol.14, issue.4, pp.619-647, 1993.
DOI : 10.1093/carcin/14.4.619

M. Kohn and R. Melnick, Effects of the structure of a toxicokinetic model of butadiene inhalation exposure on computed production of carcinogenic intermediates, Toxicology, vol.113, issue.1-3, pp.31-40, 1996.
DOI : 10.1016/0300-483X(96)03424-5

F. Bois, Modélisation toxicocinétique de la concentration de 2,3,7,8-tetrachloro-p-dioxine après ingestion chez la femme, Environnement, Risques et Santé, vol.2, 2003.

J. Hammersley and D. Handscomb, Monte Carlo Methods, 1964.

B. Davies and T. Morris, Physiological parameters in laboratory animals and humans, Pharmaceutical Research, vol.10, issue.7, pp.1093-1098, 1993.
DOI : 10.1023/A:1018943613122

R. Brown, M. Delp, S. Lindstedt, L. Rhomberg, and R. Beliles, Physiological Parameter Values for Physiologically Based Pharmacokinetic Models, Toxicology and Industrial Health, vol.191, issue.1, pp.407-84, 1997.
DOI : 10.1177/074823379701300401

A. Arms and C. Travis, Reference Physiological Parameters in Pharmacokinetics modeling, 1988.

J. Hopkins and R. Leipold, On the Dangers of Adjusting the Parameter Values of Mechanism-Based Mathematical Models, Journal of Theoretical Biology, vol.183, issue.4, pp.417-444, 1996.
DOI : 10.1006/jtbi.1996.0232

S. Greenland, Sensitivity Analysis, Monte Carlo Risk Analysis, and Bayesian Uncertainty Assessment, Risk Analysis, vol.21, issue.4, pp.579-83, 2001.
DOI : 10.1111/0272-4332.214136

L. Sweeney, T. Tyler, and C. Kirman, Proposed Occupational Exposure Limits for Select Ethylene Glycol Ethers Using PBPK Models and Monte Carlo Simulations, Toxicological Sciences, vol.62, issue.1, pp.124-163, 2001.
DOI : 10.1093/toxsci/62.1.124

F. Bois, E. Jackson, K. Pekari, and M. Smith, Population toxicokinetics of benzene, Environmental Health Perspectives, vol.104, issue.Suppl 6, pp.1405-1416, 1996.
DOI : 10.1289/ehp.961041405

A. Gelman, F. Bois, and J. Jiang, Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions, Journal of the American Statistical Association, vol.55, issue.436, pp.1400-1412, 1996.
DOI : 10.2307/2533402

URL : http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.44.2288

J. Bernardo and A. Smith, Bayesian Theory, 1994.
DOI : 10.1002/9780470316870

W. Gilks, S. Richardson, and D. Spiegelhalter, Markov Chain Monte Carlo in Practice, 1996.

A. Gelman, J. Carlin, H. Stern, and D. Rubin, Bayesian Data Analysis, 1995.

F. Bois and D. Maszle, MCSim: a simulation program, Journal of Statistical Software, vol.2, issue.9, 1997.

T. Louis, Assessing, Accommodating, and Interpreting the Influences of Heterogeneity, Environmental Health Perspectives, vol.90, pp.215-237, 1991.
DOI : 10.2307/3430871

O. Flaherty and E. , Pharmacokinetics, pharmacodynamics, and prediction of developmental abnormalities, Reproductive Toxicology, vol.11, issue.2-3, pp.413-419, 1997.
DOI : 10.1016/S0890-6238(96)00155-4

A. Racine-poon and J. Wakefield, Statistical methods for population pharmacokinetic modelling, Statistical Methods in Medical Research, vol.7, issue.1, pp.63-84, 1998.
DOI : 10.1191/096228098670696372

L. Sheiner and S. Beal, Bayesian Individualization of Pharmacokinetics: Simple Implementation and Comparison with Non-Bayesian Methods, Journal of Pharmaceutical Sciences, vol.71, issue.12, pp.1344-1352, 1982.
DOI : 10.1002/jps.2600711209

J. Wakefield and J. Bennett, The Bayesian Modeling of Covariates for Population Pharmacokinetic Models, Journal of the American Statistical Association, vol.43, issue.435, pp.917-944, 1996.
DOI : 10.2307/2986121

G. Lawrence and F. Gobas, A pharmacokinetic analysis of interspecies extrapolation in dioxin risk assessment, Chemosphere, vol.35, issue.3, pp.427-52, 1997.
DOI : 10.1016/S0045-6535(97)00108-2

X. Wang, M. Santostefano, M. Devito, and L. Birnbaum, Extrapolation of a PBPK Model for Dioxins across Dosage Regimen, Gender, Strain, and Species, Toxicological Sciences, vol.56, issue.1, pp.49-60, 2000.
DOI : 10.1093/toxsci/56.1.49

R. Ings, Interspecies scaling and comparisons in drug development and toxicokinetics, Xenobiotica, vol.75, issue.11, pp.1201-1232, 1990.
DOI : 10.3109/03602538409033558

K. Watanabe and F. Bois, Interspecies Extrapolation of Physiological Pharmacokinetic Parameter Distributions, Risk Analysis, vol.75, issue.6, pp.741-54, 1996.
DOI : 10.1016/0378-4274(93)90103-5

I. Davidson, J. Parker, and R. Beliles, Biological basis for extrapolation across mammalian species, Regulatory Toxicology and Pharmacology, vol.6, issue.3, pp.211-248, 1986.
DOI : 10.1016/0273-2300(86)90014-0

G. Van-der-mollen, S. Kooijman, and W. Slob, A Generic Toxicokinetic Model for Persistent Lipophilic Compounds in Humans: An Application to TCDD, Toxicological Sciences, vol.31, issue.1, pp.83-94, 1996.
DOI : 10.1093/toxsci/31.1.83

R. Luecke, W. Wosilait, B. Pearce, and J. Young, A computer model and program for xenobiotic disposition during pregnancy, Computer Methods and Programs in Biomedicine, vol.53, issue.3, pp.201-225, 1997.
DOI : 10.1016/S0169-2607(97)00020-5

L. Sheiner and S. Beal, Evaluation of methods for estimating population pharmacokinetic parameters -I

A. Racine-poon and A. Smith, Population Models, Statistical Methodology in the Pharmaceutical Sciences, pp.139-62, 1990.
DOI : 10.1201/b16950-6

L. Aarons, Population pharmacokinetics, International Journal of Clinical Pharmacology, Therapy, and Toxicology, vol.30, pp.520-522, 1992.

F. Bois, A. Gelman, J. Jiang, D. Maszle, L. Zeise et al., Population toxicokinetics of tetrachloroethylene, Archives of Toxicology, vol.70, issue.6, pp.347-55, 1996.
DOI : 10.1007/s002040050284

URL : https://hal.archives-ouvertes.fr/ineris-00969532

L. Claret and A. Iliadis, Nonparametric density estimation applied to population pharmacokinetics, Mathematical Biosciences, vol.133, issue.1, pp.51-68, 1996.
DOI : 10.1016/0025-5564(95)00079-8

J. Wakefield and S. Walker, Bayesian nonparametric population models: formulation and comparison with likelihood approaches, Journal of Pharmacokinetics and Biopharmaceutics, vol.25, issue.2, pp.235-53, 1997.
DOI : 10.1023/A:1025736230707

F. Bois, T. Smith, A. Gelman, H. Chang, and A. Smith, Optimal design for a study of butadiene toxicokinetics in humans, Toxicological Sciences, vol.49, issue.2, pp.213-237, 1999.
DOI : 10.1093/toxsci/49.2.213

URL : https://hal.archives-ouvertes.fr/ineris-00962757